These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 7906049)

  • 1. Marker paths. MAP Workshop (Multi-cohort Analysis Project).
    Stat Med; 1993 Nov; 12(22):2099-126. PubMed ID: 7906049
    [No Abstract]   [Full Text] [Related]  

  • 2. Markov models. MAP Workshop (Multi-cohort Analysis Project).
    Stat Med; 1993 Nov; 12(22):2127-30. PubMed ID: 7906050
    [No Abstract]   [Full Text] [Related]  

  • 3. Markers as time-dependent covariates in relative risk regression. MAP Workshop (Multi-cohort Analysis Project).
    Stat Med; 1993 Nov; 12(22):2087-98. PubMed ID: 7906048
    [No Abstract]   [Full Text] [Related]  

  • 4. Extending public health surveillance of HIV infection: information from a five cohort workshop. MAP Workshop (Multi-cohort Analysis Project).
    Stat Med; 1993 Nov; 12(22):2065-85. PubMed ID: 7906047
    [No Abstract]   [Full Text] [Related]  

  • 5. Long-term zidovudine therapy in patients with AIDS and symptomatic and asymptomatic HIV infection.
    Ebert S; Gockel K; Horowitz S; Weber P; Vogelman B; Graziano F
    Wis Med J; 1991 Apr; 90(4):161-5. PubMed ID: 1675028
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improvement of the predictive value of CD4+ lymphocyte count by beta 2-microglobulin, immunoglobulin A and erythrocyte sedimentation rate. The Multicentre Cohort Study Group.
    Schwartländer B; Bek B; Skarabis H; Koch J; Burkowitz J; Koch MA
    AIDS; 1993 Jun; 7(6):813-21. PubMed ID: 8103341
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunologic markers of AIDS progression: consistency across five HIV-infected cohorts. Multicohort Analysis Project Workshop. Part I.
    AIDS; 1994 Jul; 8(7):911-21. PubMed ID: 7946100
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma levels of viro-immunological markers in HIV-infected and non-infected Ethiopians: correlation with cell surface activation markers.
    Messele T; Brouwer M; Girma M; Fontanet AL; Miedema F; Hamann D; Rinke de Wit TF
    Clin Immunol; 2001 Feb; 98(2):212-9. PubMed ID: 11161977
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The utility of large, simple trials in the evaluation of AIDS treatment strategies.
    Ellenberg SS; Foulkes MA
    Stat Med; 1994 Mar 15-Apr 15; 13(5-7):405-15. PubMed ID: 7912842
    [No Abstract]   [Full Text] [Related]  

  • 10. Immunologic marker paths for seroconversion: single determinations of immunoglobulin A and beta 2-microglobulin are not adequate to estimate time of HIV infection. Multicohort Analysis Project Workshop. Part II.
    AIDS; 1994 Jul; 8(7):923-33. PubMed ID: 7946101
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Another AIDS drug. Azidothymidine--dideoxycytidine].
    Moosmann EB
    Fortschr Med; 1992 Jun; 110(18):28-30. PubMed ID: 1353746
    [No Abstract]   [Full Text] [Related]  

  • 12. Evaluating the role of CD4-lymphocyte counts as surrogate endpoints in human immunodeficiency virus clinical trials.
    Lin DY; Fischl MA; Schoenfeld DA
    Stat Med; 1993 May; 12(9):835-42. PubMed ID: 8101011
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Surrogate markers for AIDS treatment.
    Jacobson M
    Nurs Times; 1991 May 29-Jun 4; 87(22):49. PubMed ID: 1675013
    [No Abstract]   [Full Text] [Related]  

  • 14. Markers of risk in HIV-1.
    Krämer A; Biggar RJ; Goedert JJ
    N Engl J Med; 1990 Jun; 322(26):1886. PubMed ID: 1971915
    [No Abstract]   [Full Text] [Related]  

  • 15. [Present and future of the antiretroviral therapy].
    Martinez-Vazquez JM; Cabarcos A
    An Med Interna; 1996 Jan; 13(1):1-3. PubMed ID: 8679816
    [No Abstract]   [Full Text] [Related]  

  • 16. HIV/AIDS surveillance in Indiana.
    Fleissner ML
    Indiana Med; 1992; 85(6):486-9. PubMed ID: 1431033
    [No Abstract]   [Full Text] [Related]  

  • 17. Zidovudine in asymptomatic HIV infection.
    Berger PB
    N Engl J Med; 1993 Dec; 329(25):1895; author reply 1895-6. PubMed ID: 7902534
    [No Abstract]   [Full Text] [Related]  

  • 18. [Survival of patients with zidovudine resistant HIV].
    Gøtzsche PC; Nielsen C; Gerstoft J; Nielsen CM; Vestergaard BF
    Ugeskr Laeger; 1994 Jan; 156(2):185-6. PubMed ID: 7905217
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD4 counts as surrogate markers for progression to AIDS.
    Harris PJ
    Ann Intern Med; 1994 Jan; 120(1):88. PubMed ID: 7902690
    [No Abstract]   [Full Text] [Related]  

  • 20. Delayed-type hypersensitivity skin tests are an independent predictor of human immunodeficiency virus disease progression. Department of Veterans Affairs Cooperative Study Group.
    Gordin FM; Hartigan PM; Klimas NG; Zolla-Pazner SB; Simberkoff MS; Hamilton JD
    J Infect Dis; 1994 Apr; 169(4):893-7. PubMed ID: 7907646
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.